Polypharmacy as a prognostic factor in older patients with advanced non-small-cell lung cancer treated with anti-PD-1/PD-L1 antibody-based immunotherapy

被引：0
|
作者：
Taiki Hakozaki
Yukio Hosomi
Akihiro Shimizu
Rui Kitadai
Kie Mirokuji
Yusuke Okuma
机构：
[1] Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital,Department of Thoracic Oncology and Respiratory Medicine
[2] National Cancer Center Hospital,Department of Thoracic Oncology
来源：
Journal of Cancer Research and Clinical Oncology | 2020年 / 146卷
关键词：
Polypharmacy; Non-small cell lung cancer; Overall survival; Geriatric oncology; Comorbidity;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：2659 / 2668
页数：9
相关论文
共 50 条
  • [41] Comparative Efficacy and Safety of Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors for Refractory or Relapsed Advanced Non-Small-Cell Lung Cancer-A Systematic Review and Network Meta-Analysis
    Ando, Koichi
    Manabe, Ryo
    Kishino, Yasunari
    Kusumoto, Sojiro
    Yamaoka, Toshimitsu
    Tanaka, Akihiko
    Ohmori, Tohru
    Ohnishi, Tsukasa
    Sagara, Hironori
    CANCERS, 2021, 13 (01) : 1 - 21
  • [42] PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer
    Larsen, Trine Vilsboll
    Hussmann, Dianna
    Niesen, Anders Lade
    CANCER COMMUNICATIONS, 2019, 39
  • [43] PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
    Mei Ji
    Yan Liu
    Qing Li
    Xiao-Dong Li
    Wei-Qing Zhao
    Hanze Zhang
    Xiaofei Zhang
    Jing-Ting Jiang
    Chang-Ping Wu
    Journal of Translational Medicine, 13
  • [44] Correlation of Lung Immune Prognostic Index With Efficacy of PD-1/PD-L1 Inhibitor Combined With Chemotherapy and Prognosis in Patients With Advanced Non-Small Cell Lung Cancer
    Zhu, Zhongxiu
    Zhang, Aixia
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2023, 46 (11): : 496 - 502
  • [45] Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer
    Miyawaki, Taichi
    Naito, Tateaki
    Yabe, Michitoshi
    Kodama, Hiroaki
    Nishioka, Naoya
    Miyawaki, Eriko
    Mamesaya, Nobuaki
    Kobayashi, Haruki
    Omori, Shota
    Wakuda, Kazushige
    Ono, Akira
    Kenmotsu, Hirotsugu
    Murakami, Haruyasu
    Mori, Keita
    Harada, Hideyuki
    Takahashi, Kazuhisa
    Takahashi, Toshiaki
    SUPPORTIVE CARE IN CANCER, 2022, 30 (02) : 1633 - 1641
  • [46] PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation
    Ji, Mei
    Liu, Yan
    Li, Qing
    Li, Xiao-Dong
    Zhao, Wei-Qing
    Zhang, Hanze
    Zhang, Xiaofei
    Jiang, Jing-Ting
    Wu, Chang-Ping
    JOURNAL OF TRANSLATIONAL MEDICINE, 2015, 13
  • [47] Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)
    Liu, Si-Yang
    Wu, Yi-Long
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2020, 29 (12) : 1355 - 1363
  • [48] The influence of pharmaceutical care in patients with advanced non-small-cell lung cancer receiving combination cytotoxic chemotherapy and PD-1/PD-L1 inhibitors
    Kou, Wen
    Lin, Yan Yan
    Su, Fei
    Xiang, Yue
    Qiao, Hui
    Wu, Xin'An
    Hou, Xiao-Ming
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [49] Impact of weight loss on treatment with PD-1/PD-L1 inhibitors plus chemotherapy in advanced non-small-cell lung cancer
    Taichi Miyawaki
    Tateaki Naito
    Michitoshi Yabe
    Hiroaki Kodama
    Naoya Nishioka
    Eriko Miyawaki
    Nobuaki Mamesaya
    Haruki Kobayashi
    Shota Omori
    Kazushige Wakuda
    Akira Ono
    Hirotsugu Kenmotsu
    Haruyasu Murakami
    Keita Mori
    Hideyuki Harada
    Kazuhisa Takahashi
    Toshiaki Takahashi
    Supportive Care in Cancer, 2022, 30 : 1633 - 1641
  • [50] Anti-PD-1/PD-L1 antibody therapy for pretreated advanced nonsmall-cell lung cancer: A meta-analysis of randomized clinical trials
    Zhou, Guo-Wu
    Xiong, Ye
    Chen, Si
    Xia, Fan
    Li, Qiang
    Hu, Jia
    MEDICINE, 2016, 95 (35)
12345